Skip to main content
Premium Trial:

Request an Annual Quote

Novogene, Chipscreen Ink CDx Development Deal

NEW YORK — Genomic services provider Novogene has signed an agreement to develop a companion diagnostic for a cancer drug under development at Chipscreen Biosciences, the Chinese companies said today.

Under the terms of the deal, Novogene will develop a companion diagnostic for chiauranib, a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis, and microenvironment inflammation. Novogene will also provide molecular testing services to Chipscreen during clinical testing of the drug.

Additional terms were not disclosed.

"The collaboration between Chipscreen and Novogene will help select the right patients for the clinical development of chiauranib in several tumor types including ovarian cancer, small cell lung cancer, liver cancer, and non-Hodgkin's lymphoma," Chipscreen Executive Vice President Zhiqiang Ning said in a statement.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.